This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sundberg, T. B. Articles by Glick, G. D. Search for Related Content PubMed PubMed Citation Articles by Sundberg, T. B. Articles by Glick, G. D.

The Immunomodulatory Benzodiazepine Bz-423 Inhibits B-Cell Proliferation by Targeting c-Myc Protein for Rapid and Specific Degradation

Departments of ¹ Chemistry, ² Pediatrics, and ³ Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Anthony W. Opipari, Jr., Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 East Medical Center Drive, L4000 Women's Hospital, Ann Arbor, MI 48109. Phone: 734-764-9106; Fax: 734-615-8902; E-mail: aopipari{at}umich.edu.

Myc proteins regulate cell growth and are oncogenic in many cancers. Although these proteins are validated molecular anticancer targets, new therapies aimed at modulating myc have yet to emerge. A benzodiazepine (Bz-423) that was discovered in efforts to find new drugs for lupus was found recently to have antiproliferative effects on Burkitt's lymphoma cells. We now show that the basis for the antiproliferative effects of Bz-423 is the rapid and specific depletion of c-myc protein, which is coupled to growth-suppressing effects on key regulators of proliferation and cell cycle progression. c-Myc is depleted as a result of signals coupled to Bz-423 binding its molecular target, the oligomycin sensitivity-conferring protein subunit of the mitochondrial F₁F_o-ATPase. Bz-423 inhibits F₁F_o-ATPase activity, blocking respiratory chain function and generating superoxide, which at growth-inhibiting concentrations triggers proteasomal degradation of c-myc. Bz-423-induced c-myc degradation is independent of glycogen synthase kinase but is substantially blocked by mutation of the phosphosensitive residue threonine 58, which when phosphorylated targets c-myc for ubiquitination and subsequent proteasomal degradation. Collectively, this work describes a new lead compound, with drug-like properties, which regulates c-myc by a novel molecular mechanism that may be therapeutically useful. (Cancer Res 2006; 66(3): 1775-82)

This article has been cited by other articles:

				I. Kim, C.-W. Shu, W. Xu, C.-W. Shiau, D. Grant, S. Vasile, N. D. P. Cosford, and J. C. Reed Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1 J. Biol. Chem., January 16, 2009; 284(3): 1593 - 1603. [Abstract] [Full Text] [PDF]

				O. Nyanguile, F. Pauwels, W. Van den Broeck, C. W. Boutton, L. Quirynen, T. Ivens, L. van der Helm, G. Vandercruyssen, W. Mostmans, F. Delouvroy, et al. 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4420 - 4431. [Abstract] [Full Text] [PDF]

				N. Bhagavathula, K. C. Nerusu, A. Hanosh, M. N. Aslam, T. B. Sundberg, A. W. Opipari Jr., K. Johnson, S. Kang, G. D. Glick, and J. Varani 7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a Benzodiazepine, Suppresses Keratinocyte Proliferation and Has Antipsoriatic Activity in the Human Skin-Severe, Combined Immunodeficient Mouse Transplant Model J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 938 - 947. [Abstract] [Full Text] [PDF]